About-cancer/treatment/clinical-trials/disease/skin-cancer/treatment

Daaweynta Tijaabooyinka Caafimaadka ee Kansarka Maqaarka ee Melanoma

Tijaabooyinka caafimaad waa daraasado cilmi baaris ah oo dadka ku lug leh. Tijaabooyinka caafimaad ee liiskan waxaa loogu talagalay daaweynta kansarka maqaarka ee aan-melanoma ahayn. Dhammaan tijaabooyinka ku jira liiska waxaa taageera NCI.

Macluumaadka aasaasiga ah ee NCI ee ku saabsan tijaabooyinka bukaan socodka wuxuu sharxayaa noocyada iyo wejiyada tijaabooyinka iyo sida loo fuliyo. Tijaabooyinka caafimaad waxay eegaan habab cusub oo looga hortago, lagu ogaado, ama lagu daweeyo cudur. Waxaa laga yaabaa inaad rabto inaad ka fikirto kaqeybqaadashada tijaabada caafimaadka. La hadal dhakhtarkaaga si uu kaaga caawiyo go aansashada haddii mid kugu habboon yahay.

Tijaabooyinka 1-25 ee 118 1 2 3 4 5 Xiga>

Daaweynta Bartilmaameedka ah ee Lagu Hagayo Tijaabinta Hidaha ee Lagu Daaweynayo Bukaannada leh Burooyinka Adag ee Soo Noqda, Lymphomas, ama Multiye Myeloma (Tijaabada Baaritaanka MATCH)

Marxaladan tijaabada ah ee 'MATCH' waxay daraasad ku sameysaa sida ugu wanaagsan ee daaweynta ee ay hogaamiso baaritaanka hidda-socodka ay ugu shaqeyso bukaanada qaba burooyinka adag ama lymphomas-ka ee horumar sameeyay ka dib ugu yaraan hal xariiq oo ah daaweynta caadiga ah ama aan lagu heshiin habka daaweynta. Tijaabooyinka hiddo-wadaha ayaa fiiriya maaddada hiddo-wadaha (hiddo-wadaha) gaarka ah ee unugyada burooyinka bukaannada. Bukaannada qaba cilladaha hidde-ahaaneed (sida is-beddelka, kordhinta, ama beddelidda) ayaa laga yaabaa inay ka faa'iideystaan ​​wax badan oo ka mid ah daaweynta oo bartilmaameedsanaya cilladaha hiddo-wadaha gaarka ah ee burooyinka. Aqoonsiga cilladahan hidde-ahaaneed marka hore waxay ka caawin kartaa dhakhaatiirta inay qorsheeyaan daaweyn wanaagsan oo loogu talagalay bukaannada qaba burooyinka adag, lymphomas, ama myeloma badan.

Goobta: 1189 goobood

Nivolumab ka dib Daaweynta Isku-dhafan ee Isku-dhafan ee Daaweynta Bukaannada Heerka Khatarta Sare ee II-IIIB Kansarka Kansarka

Marxaladan tijaabada ah ee tijaabada caafimaad ee wajiga labaad ah ayaa lagu daraaseeyaa sida ugu wanaagsan ee loo yaqaan 'nivolumab' ka dib marka daaweynta isku dhafan ee isku dhafan ay ka shaqeyso daaweynta bukaannada qaba heerka sare ee kansarka dabada II-IIIB. Immunotherapy oo leh unugyada unugyada monoclonal, sida nivolumab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragalin karaa awooda unugyada burooyinka inay koraan oo ay faafaan.

Goobta: 745 goobood

Pembrolizumab Marka loo Barbardhigo Heerka U Kuurgelidda Daryeelka ee Ku Daaweynta Bukaannada Heerka Baadhitaanka Dhammaystiran ee I-III Merkel Kansarka

Marxaladani tijaabinta wajiga III waxay daraaseyneysaa sida wanaagsan ee ay u shaqeyso pembrolizumab marka la barbar dhigo heerka u kuurgalida daryeelka ee daaweynta bukaannada qaba heerka I-III Merkel kansarka unugga oo gebi ahaanba laga saaray qalliin (dib loo soo saaray). Immunotherapy oo leh unugyada unugyada monoclonal, sida pembrolizumab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragelin karaa awooda unugyada burooyinka inay koraan oo ay faafaan.

Goobta: 286 goobood

Avelumab leh ama aan lahayn Cetuximab ee Daaweynta Bukaannada qaba Kansarka Unugyada Maqaarka ee Sare

Tijaabadan wejiga II ah waxay daraasad ku samaynaysaa sida wanaagsan ee avelumab leh ama aan lahayn shaqo cetuximab lagu daaweeyo bukaanada qaba kansarka unugyada maqaarka oo ku faaftay meelo kale oo jirka ah (horumarsan). Immunotherapy oo leh unugyada unugyada monoclonal, sida avelumab iyo cetuximab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragelin karaa awooda unugyada burooyinka inay koraan oo ay faafaan.

Goobta: 277 goobood

Pembrolizumab oo leh ama aan lahayn Daaweynta shucaaca jirka ee Stereotactic ee lagu daaweynayo bukaanka qaba kansarka hormarka ama metastatic Merkel

Tijaabadan wajiga labaad ee la kala soocay ayaa daraasad ku samaynaysa sida ugu wanaagsan ee pembrolizumab leh ama aan lahayn daaweynta shucaaca jirka ee stereotactic ay ugu shaqayso daaweynta bukaanka qaba kansarka unugga ee Merkel oo ku fiday meelo kale oo jidhka ah. Immunotherapy oo leh unugyada unugyada monoclonal, sida pembrolizumab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragelin karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Daaweynta shucaaca jirka ee loo yaqaan 'Stereotactic radiation radiation' waxay isticmaashaa qalab gaar ah si loo meeleeyo bukaanka loona gaarsiiyo shucaaca burooyinka leh saxsanaanta sare. Qaabkani wuxuu dili karaa unugyada burooyinka iyadoo qiyaaso yar la qaato mudo gaaban isla markaana waxyeelo yar u geyso unugyada caadiga ah. Ku siinta pembrolizumab daaweynta shucaaca jirka ee stereotactic waxay si fiican uga shaqeyn kartaa daaweynta bukaanada qaba kansarka unugyada ee Merkel.

Goobta: 246 goobood

Wax ku oolnimada iyo Badbaadinta Daraasadda Tisotumab Vedotin ee Bukaannada qaba Burooyinka Adag

Tijaabadani waxay baran doontaa tisotumab vedotin si loo ogaado inay tahay daaweyn wax ku ool ah oo ku saabsan burooyinka adag ee qaarkood iyo dhibaatooyinka soo raaca (saamaynta aan loo baahnayn) ee dhici kara. Daaweynta waxaa la siin doonaa bukaanka saddexdii toddobaadba mar.

Goobta: 12 goobood

PD-1 ee Bukaannada leh Cudurka Kansarka Sare ee 'Basal Cell Carcinoma' Kuwaasoo Khibrad U Leh Cudurka Cudurka 'Hedgehog Pathway Inhibitor Therapy', ama Aan Dulqaadanayn Hore ee Hedgehog Pathway Inhibitor Therapy

Ujeeddada koowaad ayaa ah in lagu qiyaaso heerka jawaabta guud (ORR) ee metastatic Basal Cell Carcinoma (BCC) (kooxda 1) iyo BCC oo heer sare ah oo aan degaanka laga aqbali karin (koox 2) markii lagu daaweeyay REGN2810 oo ah monotherapy

Goobta: 15 goobood

Daraasada Wajiga II ee Tipifarnib ee Madaxa Madaxa iyo Kansarka Qoorta ee Isbedelada HRAS

Daraasada Wejiga II si loo baaro waxqabadka antitumor marka la eego heerka jawaabta ujeeddada (ORR) ee tipifarnib maadooyinka leh burooyinka horumarsan ee xambaarsan isku-beddelka HRAS iyo kuwa aan lahayn daaweyn heer sare ah oo la heli karo. Fiiro gaar ah; Kaliya kooxda 2 (Madaxa & Neck SCC) iyo kooxda 3 (SCC kale) ayaa hada furan

Goobta: 11 goobood

Daraasad Immuno-therapy ah oo baaritaan ah oo lagu baarayo amniga iyo waxtarka Nivolumab, iyo Nivolumab Isugeynta Daaweynta ee Burooyinka la xiriira Virus

Ujeedada daraasaddan si loo baaro amniga iyo waxtarka nivolumab, iyo daaweynta isku-darka nivolumab, si loo daaweeyo bukaannada qaba burooyinka la xiriira fayraska. Feyrasyada qaarkood ayaa lagu yaqaan inay door ka ciyaaraan sameynta burooyinka iyo koritaanka. Daraasadani waxay baari doontaa saameynta daawooyinka daraasadda, bukaanada leh noocyada burooyinka soo socda: - Cancer Canal Canal-Mar dambe ma diiwaan galiso nooca burooyinka kansarka ilmo galeenka - Epstein Barr Virus (EBV) kansarka caloosha wanaagsan - Mar dambe ma diiwaangelin tan nooca burooyinka - Kansarka Unugyada Kansarka - Kansarka Penile-Mar dambe ma diiwaangeliyo nooca burooyinkaan - Kansarka siilka iyo xubinta taranka-Mar dambe ma diiwaan galinayo nooca burooyinkaan - Kansarka Nasopharyngeal - Mar dambe ma diiwaangelinayo nooca buro - Madaxa iyo Kansarka Qoorta

Goobta: 10 goobood

Pembrolizumab iyo Goobta Ka Dib Qalliinka iyo Shucaaca Kaqeybgaleyaasha Iyada oo leh Maxalli Carcinoma Qanjirrada Maxalliga ah ee Deegaanka ah (MK-3475-630 / KEYNOTE-630)

Tani waa kala sooc, laba-indhoole, daraasad isbarbardhigaysa pembrolizumab oo leh placebo loo siiyay daaweyn adjuvant ah oo kaqeybgalayaasha leh halista sare ee maxalliga ah ee unugyada unugyada unugyada 'carcanooma' (LA cSCC) ee lagu sameeyay qalliin ujeeddo daaweyn ah oo lagu daro shucaaca Qiyaasta asaasiga ahi waxay tahay in pembrolizumab ay ka sareyso placebo sii kordhinta badbaadada bilaashka ah ee soo noqnoqda (RFS).

Goobta: 10 goobood

Daraasadani waxay Qiimeyneysaa KRT-232, Nobel Oral Molecule Inhibitor of MDM2, ee loogu talagalay Daaweynta Bukaannada (p53WT) Merkel Cell Carcinoma Kuwa Ku Fashilmay Kahortagga PD-1 / PD-L1 Immunotherapy

Daraasadani waxay qiimeyneysaa KRT-232, oo ah sheeko-yare yar-yar oo xakameynaya MDM2, oo loogu talagalay daaweynta bukaannada qaba Merkel Cell Carcinoma (MCC) oo ku guuldareystay daaweynta ugu yaraan hal anti-PD-1 ama anti-PD-L1 immunotherapy. Ka-hortagga MDM2 waa qaab cusub oo ficil ah oo ka socda MCC. Daraasadani waa Wajiga 2, Buug-Furan, Daraasad Gacan-keli ah ee KRT-232 ee Bukaannada qaba p53 Wild-Type (p53WT) Merkel Cell Carcinoma

Goobta: 11 goobood

Daraasad ku saabsan XmAb®23104 ee Mawduucyada leh Burooyin Adag oo Xul ah (DUET-3)

Tani waa Wajiga 1, qaadasho badan, daraasad kordhinta qiyaasta kor u qaadista si loo qeexo MTD / RD iyo nidaamka XmAb23104, si loo sharaxo nabadgelyada iyo dulqaadka, si loo qiimeeyo PK iyo difaaca jirka, iyo in si horudhac ah loo qiimeeyo dhaqdhaqaaqa ka hortagga burooyinka ee XmAb23104 maadooyinka la xushay burooyinka adag ee horumarsan.

Goobta: 9 goobood

Adjuvant Avelumab oo ku jira Kansarka unugyada ee 'Merkel Cell Cancer'

Marxaladan tijaabada ah ee la kala soocay III waxay daraasad ku samaynaysaa sida wanaagsan ee avelumab ugu shaqeyso daaweynta bukaanada qaba kansarka unugga ee Merkel oo ku faafay qanjidhada qanjidhka isla markaana qalliin lagu sameeyay ama aan lahayn shucaac shucaac ah. Unugyada difaaca jirka ee Monoclonal, sida avelumab, ayaa kicin kara habka difaaca jirka waxayna faragalin ku yeelan karaan awooda unugyada burooyinka inay koraan oo ay faafaan.

Goobta: 10 goobood

QUILT-3.055: Daraasad ku saabsan ALT-803 oo ku jirta Isku-darka PD-1 / PD-L1 Isbaaroolaha Isbitaalka ee Bukaannada qaba Kansarka Sare

Tani waa Wajiga IIb, hal gacan, multicohort, daraasad calaamadeysan oo calaamado badan oo ALT-803 ah oo ay weheliso baaritaanka kontoroolka baaritaanka FDA-ee la ansixiyay ee PD-1 / PD-L1 ee bukaanada qaba kansarka horumarsan ee horumarka sameeyay ka dib jawaabta bilowga ah daaweynta PD-1 / PD-L1 daaweynta xakamaynta kantaroolka. Dhammaan bukaanada waxay heli doonaan daaweynta isku dhafan ee PD-1 / PD-L1 isbaaro xakameynaha oo lagu daray ALT-803 illaa iyo 16 wareegyada. Wareeg kasta waa lix toddobaad muddada. Dhamaan bukaanada waxay heli doonaan ALT-803 hal mar 3dii asbuucba. Bukaanku sidoo kale waxay heli doonaan isla xakameyn xakameeye oo ay heleen intii lagu jiray daweyntoodii hore. Qiimeynta shucaaca ayaa dhici doonta dhamaadka wareeg kasta oo daaweyn ah. Daaweyntu waxay socon doontaa illaa 2 sano, ama ilaa inta bukaanku la kulmayo la xaqiijiyey cudurka horusocodka ama sunta aan la aqbali karin, ka noqoshada oggolaanshaha, ama haddii Baaruhu uu dareemo inaysan dan ugu jirin bukaanka inuu sii wado daaweynta. Bukaannada waxaa loo raaci doonaa horumarka cudurka, daaweynta ka dib, iyo badbaadada illaa 24 bilood ee la soo dhaafay maamulkii ugu horreeyay ee daroogada daraasadda.

Goobta: 9 goobood

Badbaadada, U dulqaadashada, Difaaca jirka, iyo Waxqabadka Antitumor ee GEN-009 Tallaalka la Adkaado

Daraasaddan, Genocea waxay qiimeyneysaa baaritaan, shaqsi gaar ah oo tallaal ah, GEN-009, oo loo soo saaray daaweynta bukaannada qaba burooyinka adag. Qalab lahaansho oo ay soo saartay Genocea, oo loo yaqaan 'ATLAS ™' (Antigen Lead Acquisition System) ayaa loo isticmaali doonaa in lagu aqoonsado neoantigens-ka buro bukaan kasta oo ay aqoonsan tahay unugyadooda CD4 iyo / ama CD8 T. Neoantigens-ka la aqoonsaday ee ATLAS ayaa markaa lagu dari doonaa talaalka shakhsi ahaaneed ee bukaanka qaab peptides dheer oo la soo saaray (SLPs).

Goobta: 9 goobood

Daraasad ku saabsan NKTR-262 ee Isku-darka NKTR-214 iyo NKTR-214 Plus Nivolumab ee Bukaannada qaba Dhibaatooyinka Burooyinka Deegaanka ee Horumarka leh ama Metastatic Solid

Bukaannadu waxay heli doonaan intra-tumoral (IT) NKTR-262 wareegyada daaweynta 3-toddobaad. Inta lagu jiro Qeybta 1 ee kordhinta qiyaasta ee tijaabada, NKTR-262 waxaa lagu dari doonaa maamulka nidaamka bempegaldesleukin. Kadib go'aaminta qiyaasta Wajiga 2 ee lagu taliyey (RP2D) ee NKTR-262, inta udhaxeysa 6 iyo 12 bukaan ayaa laga qori karaa RP2D si loo sii cadeeyo astaanta badbaadada iyo dulqaadashada isku darka NKTR 262 oo lagu daray bempegaldesleukin (doublet) ama NKTR 262 plus bempegaldesleukin oo lagu daro nivolumab (triplet) ee Cohorts A iyo B, siday u kala horreeyaan. Qeybta ballaarinta Qeybta 2, bukaannada waxaa lagu daaweyn doonaa labalaab ama seddexlaab markii ay soo noqnoqdeen / diidanaayeen iyo khadadkii hore ee daaweynta.

Goobta: 14 goobood

Tijaabin kala sooc ah oo ah 'Pembrolizumab & Radiotherapy Versus Radiotherapy' oo ku jirta Khatarta Halis Sare ee Cadka Sarcoma ee Xadka

Kani waa calaamad furan, wejiyo badan oo hay'adeed II daraasad aan kala sooc lahayn ah oo isbarbardhigaya shucaaca neoadjuvant shucaaca oo ay ku xigto qalliin qalliin oo lagu sameeyo neoadjuvant pembrolizumab oo leh shucaac isku mid ah, oo ay ku xigto qalliin qalliin iyo dheellitir dheeri ah. Wadarta muddada pembrolizumab waxay noqon doontaa hal sano gacanta cududda.

Goobta: 10 goobood

Daaweynta shucaaca ee 'Proton Beam' ama Photon-based Intensiveity-Modized Therapy ee lagu daaweynayo bukaanada qaba Kansarka Salivary Gland, Cancer maqaarka, ama Melanoma

Tijaabadan wajiga labaad ee la kala soocay ayaa daraasad ku samaynaysa dhibaatooyinka soo raaca ee loo yaqaan 'proton beam' ama daaweynta shucaaca ee ku saleysan ficil-ku-saleysan ee lagu daweynayo bukaannada qaba kansarka qanjidhada candhuufta, kansarka maqaarka, ama melanoma. Daaweynta shucaaca beenta ah ee loo yaqaan 'Proton beam therapy' waxay isticmaashaa waxyaabo yar yar oo lagu soo oogay si toos shucaac ugu geeyo burada waxayna u keeni kartaa dhaawac yar unugyada caadiga ah. Daaweynta shucaaca ku-meel-gaadhka ah ee loo yaqaan 'Intensity-modulated or photon beam therapy' waxay isticmaashaa raajada tamarta sare leh ee loo qaabeeyey in lagu daaweeyo burooyinka sidoo kale waxay u keeni kartaa dhaawac yar unugyada caadiga ah. Wali lama oga in daaweynta shucaaca ee loo yaqaan 'proton beam therapy therapy' ay ka waxtar badan tahay ficil-ku-saleysan ficil-ku-saleysan habka shucaaca ee daaweynta bukaanka qaba kansarka qanjidhada candhuufta, kansarka maqaarka, ama melanoma.

Goobta: 8 goobood

Ciribtirka Daaweynta Maskaxda ee Maqaarka elektiroonigga ah ee lagu daaweynayo bukaanada waayeelka ah ee Lagu Baadho Marxaladda Hore Marxaladda Hore ee Kansarka ama Kansarka Maqaarka

Tijaabadan tijaabada ah ee tijaabada ah waxay daraasad ku sameysaa sida wanaagsan ee qalabka daaweynta maqaarka elektaroonigga ah (ESSB) ay ugu shaqeyso daaweynta bukaanada da'da weyn ee dhowaan la ogaadey marxaladda hore ee unugga aasaasiga ah ama kansarka maqaarka maqaarka. ESSB waa nooc ka mid ah daaweynta shucaaca ee loo isticmaalo maqaarka maqaarka si loo dhigo ilaha shucaaca elektarooniga ah si loogu daaweeyo kansarka maqaarka. Maqaarka marsadayaasha maqaarku waa wareegsan yihiin, saxanno siman oo ku xiran mashiinka daaweynta shucaaca, waxayna u siinayaan shucaaca daaweynta. ESSB waxay u oggolaan kartaa burooyinka in la daaweeyo iyadoo unugyada caafimaadka qaba ee hoose aysan waxyeeleynin shucaaca.

Goobta: 8 goobood

Daaweynta shucaaca jirka ee jimicsiga ee lagu daaweynayo bukaanada qaba kansarka naasaha ee leh xaddidan horukaca ee ka hortagayaasha kahortaga

Tijaabadan wejiga II ah waxay daraasad ku samaynaysaa sida ugu wanaagsan ee daaweynta shucaaca jirka ee shucuur ahaaneed ay ugu shaqeyso daaweynta bukaanada qaba kansarka ku faafay meelaha kale ee jirka iyadoo horumar xaddidan uu jiro inta lagu jiro xannibaadda isbaarada. Daaweynta shucaaca jirka ee loo yaqaan 'Stereotactic radiation radiation' waxay isticmaashaa qalab gaar ah si loo meeleeyo bukaanka loona gaarsiiyo shucaaca burooyinka leh saxsanaanta sare. Qaabkani wuxuu dili karaa unugyada burooyinka iyadoo qiyaaso yar la qaato mudo gaaban isla markaana waxyeelo yar u geyso unugyada caadiga ah.

Goobta: 7 goobood

Cabozantinib S-malate iyo Cetuximab ee Daaweynta Bukaannada leh Madaxa Metastatic iyo Kansarka Unugyada Kansarka

Tijaabadan wajiga 1aad waxay tijaabineysaa waxyeelada iyo qiyaasta ugu wanaagsan ee cabozantinib S-malate iyo marka la siinayo cetuximab si loogu daaweeyo bukaanada qaba kansarka unugyada madaxa iyo qoorta oo ku faaftay meelo kale oo jirka ah. Cabozantinib S-malate wuxuu yareyn karaa koritaanka unugyada kansarka isagoo goynaya saadka dhiiga ee kansarku u baahan yahay si uu u noolaado una koro. Immunotherapy oo leh unugyada unugyada monoclonal, sida cetuximab, waxay sababi kartaa isbeddel ku dhaca habka difaaca jirka waxayna faragalin kartaa awoodda unugyada burooyinka inay koraan oo ay faafaan. Bixinta cabozantinib S-malate iyo cetuximab ayaa si fiican uga shaqeyn kara daaweynta bukaanada qaba kansarka madaxa iyo qoorta.

Goobta: 7 goobood

Amniga, Waxqabadka Hordhaca ah iyo PK ee Isatuximab (SAR650984) Kalidaa ama Isugeynta Atezolizumab ee Bukaannada qaba Xanuunada Hormarsan

Ujeeddooyinka Aasaasiga ah: - Wajiga 1: Si loo tilmaamo badbaadada iyo u dulqaadashada isatuximab oo ay weheliso atezolizumab ee kaqeybgalayaasha leh hepatocellular carcinoma (HCC), platinum-refractory soo noqnoqda / metastatic squamous cell carcinoma ee madaxa iyo qoorta (SCCHN), platinum u adkaysta / kansarka ugxan-yar ee epithelial diirran (EOC), ama soo noqnoqda glioblastoma multiforme (GBM), iyo in la go'aamiyo qiyaasta Wajiga 2 ee lagu taliyay (RP2D). - Wajiga 2: Si loo qiimeeyo heerka jawaabta (RR) ee isatuximab oo ay weheliso atezolizumab ee kaqeybgalayaasha HCC ama SCCHN ama EOC. - Wajiga 2: Si loo qiimeeyo heerka badbaadada bilaashka ah ee horumarka ee 6 bilood (PFS-6) ee isatuximab oo lagu daro atezolizumab, ama hal wakiil oo ka mid ah kaqeybgalayaasha GBM. Ujeeddooyinka Sare: - Si loo qiimeeyo astaanta badbaadada ee daaweynta monoteraga ah ee loo yaqaan 'isatuximab monotherapy' (GBM kaliya), ama lagu daro atezolizumab ee Wajiga 2. - Si loo qiimeeyo difaaca jirka ee isatuximab iyo atezolizumab. - Si loo sifeeyo astaanta dawada dawada (PK) ee wakiilka keliya ee isatuximab (GBM kaliya) iyo atezolizumab oo lagu daro isatuximab. - Si loo qiimeeyo waxtarka guud ee isatuximab oo lagu daro atezolizumab, ama hal wakiil (GBM kaliya).

Goobta: 7 goobood

Daraasad ku saabsan INCMGA00012 ee Metastatic Merkel Cell Carcinoma (POD1UM-201)

Ujeedada daraasaddan ayaa ah in la qiimeeyo dhaqdhaqaaqa caafimaad iyo badbaadada INCMGA00012 ee kaqeybgalayaasha oo leh heer sare / metastatic Merkel cell carcinoma (MCC).

Goobta: 8 goobood

Lenvatinib Mesylate iyo Cetuximab ee Daaweynta Bukaannada leh Madaxa Soo noqnoqda ama Metastatic iyo Neck Squamous Cell Carcinoma ama Cutubka Taranka ee Cudurka Kansarka

Marxaladan tijaabada ah ee I / Ib waxay daraasad ku samaynaysaa qiyaasta ugu fiican iyo waxyeelada lenvatinib mesylate iyo cetuximab ee lagu daaweynayo bukaanka qaba madaxa iyo qoorta unugyada kansarka unugyada maqaarka ee soo noqnoqda (soo noqnoqda) ama ku faafa meelaha kale ee jirka (metastatic) ). Lenvatinib mesylate wuxuu joojin karaa koritaanka unugyada burooyinka isagoo xannibaya qaar ka mid ah enzymes-ka loo baahan yahay koritaanka unugyada. Unugyada difaaca jirka ee Monoclonal, sida 'cetuximab', waxay faragalin ku yeelan kartaa awooda unugyada burooyinka inay koraan oo ay faafaan. Siinta lenvatinib mesylate iyo cetuximab ayaa si fiican uga shaqeyn kara daaweynta bukaanada leh madaxa iyo qoorta unugyada kansarka unugyada jirka ama maqaarka maqaarka maqaarka.

Goobta: 7 goobood

PEN-221 ee Somatostatin Receptor 2 Muujinta Kansarrada Hormarsan oo ay kujiraan Protocol-ka Neuroendocrine iyo Protocol-ka Kansarka Sambabka Yar Yar PEN-221-001 waa calaamad furan, wejiyada badan Wejiga 1 / 2a daraasad lagu qiimeynayo PEN-221 bukaanada qaba SSTR2 oo muujineysa nafaqeynta caloosha sare (GEP) ama sambabada ama thymus ama burooyinka kale ee neuroendocrine ama kansarka sanbabada ee unug yar ama kansarka sanbabada weyn ee neuroendocrine carcinoma.

Goobta: 7 goobood

1 2 3 4 5 Xiga> Machadka Kansarka Qaranka